CHAMPIONS ONCOLOGY, INC. (NASDAQ:CSBR) Files An 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

0

CHAMPIONS ONCOLOGY, INC. (NASDAQ:CSBR) Files An 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

Item 5.03

Amendments to Articles of Incorporation or Bylaws; Change
in Fiscal Year.
On May 9, 2017, the board of directors (the Board) of Champions
Oncology, Inc. (the Company) approved an amendment to Section
2.10 of the Companys bylaws. Previously, such provision stated
that any director of the Company may be removed with cause by the
affirmative vote of the holders of seventy-five percent (75%) of
all the votes entitled to be cast for the election of directors,
but no director may be removed by the stockholders without cause.
As amended, such provision now states that, subject to the rights
of the holders of any series of preferred stock then outstanding,
any director of the Company may be removed with or without cause
by the affirmative vote of the holders of at least a majority of
all the votes entitled to be cast for the election of directors.
Item 9.01
Financial Statements and Exhibits.
(d) Exhibits.
The following exhibit is filed herewith:
Exhibit No. Description
3.1 Amended and Restated Bylaws


About CHAMPIONS ONCOLOGY, INC. (NASDAQ:CSBR)

Champions Oncology, Inc. is engaged in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. The Company has two business segments: Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). The POS segment provides physicians and patients information to help guide the development of personalized treatment plans. The TOS segment provides services to pharmaceutical and biotechnology companies seeking personalized approaches to drug development. Its TumorGraft Technology Platform consists of processes, physical tumors and information that it uses to personalize the development and use of oncology drugs. Each tumor from patients that it has preserved for implantation in mice, along with the patient data and molecular information associated with the tumors, are known as TumorGrafts or Patient Derived XenoGrafts of PDX Models. The collection of TumorGrafts is referred to as the Company’s TumorBank.

CHAMPIONS ONCOLOGY, INC. (NASDAQ:CSBR) Recent Trading Information

CHAMPIONS ONCOLOGY, INC. (NASDAQ:CSBR) closed its last trading session up +0.11 at 2.45 with 52,624 shares trading hands.